Acadia Healthcare Company, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 19, 2021, by Acadia Healthcare Company, Inc. The report details the completion of a significant divestiture transaction involving the Company's U.K. business operations.
Key Financial Metrics and Transaction Details
The Company completed the sale of its entire U.K. business, operated under the Priory Group brand, to RemedcoUK Limited (owned by funds managed by Waterland Private Equity Fund VII). Key financial figures for the transaction include:
- Purchase Price: Approximately £1,078 million.
- Net Proceeds: Approximately $1,350 million USD.
- Net Proceeds Composition: Proceeds are net of transaction costs and the settlement of existing foreign currency hedging liabilities, calculated based on the current GBP/USD exchange rate at the time of closing.
The filing does not provide specific standalone revenue, profit, cash flow, or margin figures for the divested unit or the consolidated entity for a specific reporting period, as this is a transaction completion report rather than a periodic financial statement.
Material Changes
The primary material change is the exit from the U.K. market. The Company no longer holds an ownership interest in AHC-WW Jersey Limited, the subsidiary that constituted its U.K. operations. This transaction significantly alters the Company's geographic footprint and asset base.
Guidance, Outlook, and Risks
The filing does not contain updated forward-looking guidance, management commentary on future strategy, or specific risk factors related to the transaction beyond the standard disclosure of the deal completion. Unaudited pro forma condensed consolidated financial statements giving effect to the transaction are included as Exhibit 99.1 but are not detailed in the text of this summary.
Key Facts for Investor Verification
- Verify the exact GBP/USD exchange rate used to calculate the $1,350 million net proceeds.
- Review Exhibit 99.1 for the unaudited pro forma financial statements to understand the impact on the Company's balance sheet and liquidity post-transaction.
- Confirm the specific amount of transaction costs and foreign currency hedging liabilities settled to reconcile the gross purchase price to the net proceeds.
- Assess the strategic rationale for the divestiture as it relates to the Company's remaining U.S. and international operations.